文献速递心力衰竭与心肌病心律失常

英国儿童肥厚型心肌病的临床表现与生存:四十年回顾性研究

Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom.
PubMed 文献 · Eur Heart J · 2019-01-01

病因以非综合征型为主(63%),其次为RASopathy(18.3%)、Friedreich共济失调(8.6%)和先天性代谢缺陷(9%)。5年无死亡或移植生存率为90.6%,总死亡率和心脏性猝死率随时间无变化,但婴儿期发病或合并代谢缺陷者预后更差。

要点

  • 儿童HCM病因异质,非综合征型占63%,RASopathy和代谢缺陷在婴儿期更常见。
  • 5年无死亡或移植生存率90.6%,总死亡率和SCD率四十年无改善。
  • 婴儿期发病或合并先天性代谢缺陷者5年生存率更低(80.5%或66.4%)。

核心结论

  • 儿童HCM是一种异质性疾病,结局取决于发病年龄和病因;总体死亡率和SCD率未随时间改善,仍高于成人HCM。

主要发现

  • 病因构成:非综合征型433例(63%),RASopathy 126例(18.3%),Friedreich共济失调59例(8.6%),先天性代谢缺陷64例(9%)。
  • 婴儿期(159例,23%)更常见RASopathy(42% vs 11.2%,P<0.0001)或代谢缺陷(18.9% vs 6.4%,P<0.0001)。
  • 家族性疾病患者中位诊断年龄更高(11岁 vs 6岁,P<0.0001),其中141例(58%)在12岁前诊断。
  • 死亡最常见为心脏性猝死(20例,2.9%);婴儿期发病或合并代谢缺陷者5年生存率分别为80.5%和66.4%。

临床怎么用

  • 儿童HCM需根据发病年龄和病因进行风险分层,婴儿期发病或合并代谢缺陷者应加强监测。
  • 尽管总死亡率未改善,SCD仍占死亡较大比例,需关注综合征型和非综合征型患者的猝死风险。

局限性

  • 回顾性研究设计,可能存在选择偏倚和信息偏倚。
  • 单国队列,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Understanding the spectrum of disease, symptom burden and natural history are essential for the management of children with hypertrophic cardiomyopathy (HCM). The effect of changing screening practices over time has not previously been studied. This study describes the clinical characteristics and outcomes of childhood HCM over four decades in a well-characterized United Kingdom cohort. METHODS AND RESULTS: Six hundred and eighty-seven patients with HCM presented at a median age of 5.2 years (range 0-16). Aetiology was: non-syndromic (n = 433, 63%), RASopathy (n = 126, 18.3%), Friedreich's ataxia (n = 59, 8.6%) or inborn errors of metabolism (IEM) (n = 64, 9%). In infants (n = 159, 23%) underlying aetiology was more commonly a RASopathy (42% vs. 11.2%, P < 0.0001) or IEM (18.9% vs. 6.4% P < 0.0001). In those with familial disease, median age of presentation was higher (11 years vs. 6 years, P < 0.0001), 141 (58%) presented <12 years. Freedom from death or transplantation was 90.6% (87.9-92.7%) at 5 years (1.5 per 100 patient years) with no era effect. Mortality was most frequently sudden cardiac death (SCD) (n = 20, 2.9%). Children diagnosed during infancy or with an IEM had a worse prognosis (5-year survival 80.5% or 66.4%). Arrhythmic events occurred at a rate of 1.2 per 100 patient years and were more likely in non-syndromic patients (n = 51, 88%). CONCLUSION: This national study describes a heterogeneous disease whose outcomes depend on the age of presentation and aetiology. Overall mortality and SCD rates have not changed over time, but they remain higher than in adults with HCM, with events occurring in syndromic and non-syndromic patients.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Norrish G, Field E, Mcleod K, et al. Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom. Eur Heart J. 2019. PMID: 30535072. doi:10.1093/eurheartj/ehy798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。